Rubicon Research

    RUBICON
    Pharma
    ₹1,658.30
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹27,451 Cr

    P/E
    85.04
    Day range
    ₹1,640.00 – ₹1,697.00
    52-week range
    ₹609.25 – ₹1,899.00
    Volume
    61,438
    Open
    ₹1,683.90
    Prev close
    ₹1,683.90

    Latest results · Q2 FY27(consolidated)Revenue ₹576 Cr+39.9%Profit ₹90 Cr+67.9%Margin 15.7%YoY vs the same quarter last year

    3 red flags to read up on

    • high

      Promoters selling in the market

      Promoter group sold a net ₹2325 Cr on the open market in 90 days · 26 Aug 2026

    • high

      Under Additional surveillance (ASM)

      The exchange has put this stock under Additional surveillance (ASM), Stage I · 18 Nov 2026

    • medium

      Promoter holding falling

      51.25%, down 8.74 pts since 2025-10-15 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 60 / 100

    Factor percentiles

    Value16
    Quality72
    Momentum83
    Low volatility68

    Derived metrics

    Earn. yield
    1.2%
    Graham no.
    ₹193.62
    vs Graham
    -88.3%
    ROE ÷ P/B
    1.4%
    12-1 mom.
    +143.2%
    Return / vol
    3.81
    Magic Formula
    #373
    Piotroski
    5/6
    FCF yield
    -0.1%
    PEG
    1.25

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Rubicon ResearchRUBICON₹27,451 Cr85.0419.5427.0%28.0%25.0%0.35+39.8%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 52m ago

    Headlines about Rubicon Research from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    85.2
    Price / Book
    19.37
    ROE (FY26)
    27.0%
    ROCE (latest year)
    28%
    Dividend yield
    0.09%

    Moving averages (NSE)

    20-day
    ₹1,622.48
    Price above
    50-day
    ₹1,643.66
    Price above
    200-day
    ₹1,263.8
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +64.5%
    Revenue YoY (Sep 2026)
    +39.8%
    Profit YoY (Sep 2026)
    +66.7%
    Operating margin
    25.0%
    Net margin
    15.6%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr
    • Revenue
    • Net profit

    Operating margin

    Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-600 Cr-400 Cr-200 Cr0 Cr200 Cr400 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY21FY22FY23FY24FY25FY26-20%0%20%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr500 Cr1K Cr1.5K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x1x2x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales296313358352412476514534576
    Expenses234244286273318367395405432
    Operating Profit6270727994108119129144
    OPM %21%22%20%22%23%23%23%24%25%
    Other Income300114362
    Interest781211111010911
    Depreciation8910101212121518
    Profit before tax49535160729199110117
    Tax %30%28%29%27%25%20%22%23%23%
    Net Profit343836435473778590
    EPS in Rs₹2.23₹2.47₹2.35₹2.80₹3.49₹4.42₹4.65₹5.13₹5.47

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days106

    -52 days since Mar 2021

    Inventory Days550

    +42 days since Mar 2021

    Days Payable285

    +14 days since Mar 2021

    Cash Conversion Cycle371

    -24 days since Mar 2021

    Working Capital Days104

    -45 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations. [1]

    Strengths

    • Company is expected to give good quarter
    • Company has delivered good profit growth of 52.0% CAGR over last 5 years
    • Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%

    Risks

    • Stock is trading at 19.6 times its book value
    • Promoter holding has decreased over last quarter: -8.51%
    • Working capital days have increased from 68.8 days to 104 days

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +41%
    3 Years
    +65%
    TTM
    +46%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +52%
    3 Years
    +155%
    TTM
    +89%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    —
    1 Year
    +125%

    Return on Equity

    10 Years
    —
    5 Years
    +16%
    3 Years
    +27%
    Last Year
    +27%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter59.99%59.86%59.76%51.25%-8.51 pp
    FII7.99%7.54%7.52%9.01%+1.49 pp
    DII9.45%10.02%9.43%15.73%+6.30 pp
    Public22.57%22.57%23.29%24.03%+0.74 pp

    Filed with NSE for Sept 2026: promoters 51.25%, public 48.75%

    Analysts & fund holdings

    100%
    100% recommend buy
    2 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E85.0 vs 45.1
    Sector P/B6.03

    Who holds the shares, quarter by quarter

    Mutual funds 13.78% (+6.55 pp)
    Sept 25
    Oct 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters51.3%
    • Foreign institutions9.0%
    • Mutual funds13.8%
    • Insurance0.2%
    • Other domestic institutions1.8%
    • Retail3.3%
    • Others20.7%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Kotak Mid Cap Fund2.18%0.94%+0.13 pp
    Motilal Oswal Small Cap Fund1.27%4.27%-0.15 pp
    HDFC Balanced Advantage Fund1.04%0.28%+0.28 pp
    SBI Multicap Fund1.00%1.22%+1.22 pp
    Kotak Large & Mid Cap Fund0.96%0.87%+0.87 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Avg

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 268 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    43.9%
    Downside volatility
    34.5%
    Worst 5% of days
    3.3%
    Average of that tail
    4.5%
    Max drawdown (1Y)
    23.4%
    Below its peak
    10.9%

    Against the market

    Beta vs Nifty 50
    0.34
    Correlation
    0.11
    Relative strength (3M)
    -11.7%
    ATR (14)
    4.1%

    Return

    Return 1M
    +9.9%
    Return 3M
    -7.8%
    Return 6M
    +66.3%
    Return 1Y
    +167.4%
    vs 200-day average
    +31.2%

    Momentum

    RSI (14)
    51.8
    MACD histogram
    4.23
    Stochastic %K
    50.2
    ADX (14)
    19.0
    +DI / −DI
    16.6 / 21.0
    Money flow index
    59.5

    Participation

    Delivery (20d avg)
    51.2%
    vs its 60-day baseline
    +0.0 pts
    Volume vs 20-day
    -1.0σ
    Close vs day's VWAP
    -0.2%
    52-week position
    84 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — failed
    Free cash flow
    -₹24 Cr
    FCF yield
    -0.1%
    Cash conversion
    0.83
    Accruals ratio
    0.018
    Net debt
    ₹292 Cr
    Net debt / equity
    0.21
    EV / sales
    13.21
    PEG
    1.25
    Capex intensity
    16.4%
    Revenue CAGR
    39.9%
    Profit CAGR
    67.9%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹2329 Cr
    0 buys · ₹0
    15 sells · ₹2329 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    GIRISH SUBRAMANIAM IYER
    Employee · Market Sale
    Sell1,000₹18.1 L15 Sept 2026
    GIRISH SUBRAMANIAM IYER
    Employee · Market Sale
    Sell1,500₹27.3 L15 Sept 2026
    GIRISH SUBRAMANIAM IYER
    Employee · Market Sale
    Sell1,296₹23.2 L15 Sept 2026
    GIRISH SUBRAMANIAM IYER
    Employee · Market Sale
    Sell3,000₹54.9 L15 Sept 2026
    Vinayak Sawant
    Employee · Market Sale
    Sell1,100₹20.3 L4 Sept 2026
    Vinayak Sawant
    Employee · Market Sale
    Sell1,100₹20.3 L4 Sept 2026
    Vinayak Sawant
    Employee · Market Sale
    Sell1,100₹20.3 L4 Sept 2026
    Vinayak Sawant
    Employee · Market Sale
    Sell1,100₹20.3 L4 Sept 2026
    Vinayak Sawant
    Employee · Market Sale
    Sell1,100₹20.3 L4 Sept 2026
    Vinayak Sawant
    Employee · Market Sale
    Sell1,100₹20.3 L4 Sept 2026
    General Atlantic Singapore RR Pte Ltd
    Promoter · Market Sale
    Sell1,46,927₹25.4 Cr28 Aug 2026
    General Atlantic Singapore RR Pte Ltd
    Promoter · Market Sale
    Sell1,38,53,073₹2300 Cr28 Aug 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹1.50

      Dividend - Rs 1.50 Per Share

      7 Aug 2026
      ex-date

    Company announcements

    Company Update
    Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -US FDA Inspection Of The Company's Manufacturing Facility In Satara, Maharashtra, India.

    Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - US FDA inspection of the Company's manufacturing facility in Satara, Maharashtra, India

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Intimation under Regulation 30 of the SEBI (Listing Obligations and Dislcosure Requirements) Regulatoins 2015, (SEBI Listing Regulations) ESOP alottment

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of Trading Window Closure

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for General Atlantic Singapore RR Pte Ltd

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for General Atlantic Singapore RR Pte Ltd

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting Results along with the Scrutinizers Report of the 27th Annual General Meeting of the Company, held on Wednesday, 26th August 2026.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Summary of the Proceedings of the 27th Annual General Meeting of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Trascript of Earnings Call Q1 FY 2026-27

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication

    Company Update
    Audio Recording Of Earnings Conference Call For The Quarter Ended 30Th June, 2026.

    Audio Recording of earnings conference call for the quarter ended 30th June, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    Monitoring Agency Report for the Quarter ended June 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Disclosure under Regulation 30 (SEBI LODR) Outcome of Board Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation

    Board Meeting
    Board Meeting Outcome for Unaudited Financials Results For Quarter Ended June 30, 2026

    Unaudited Financials Results for Quarter ended June 30, 2026

    Filed with BSE (scrip 544578); the last 45 days. Documents open at bseindia.com.

    Documents

    Annual reports

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Rubicon Research: common questions

    Answered from the figures on this page.

    Rubicon Research last traded at ₹1,658.30 (NSE, as of 18 Nov 2026). The last session moved it down 1.52%.

    Rubicon Research is valued at about ₹27,451 crore (NSE, as of 18 Nov 2026).

    Rubicon Research trades at a price-to-earnings ratio of 85.04 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Rubicon Research has traded between ₹609.25 and ₹1,899.00 over the past 52 weeks, to 18 Nov 2026. It is currently 81% of the way up that range.

    Rubicon Research (RUBICON) is classified under Pharma on this site's screener.